Summary of Travere Therapeutics Q3 2025 Earnings Call

1Key Financial Results and Metrics

Net Product Sales: $113.2 million, with FILSPARI contributing approximately $90.9 million (up 155% year-over-year).

Total Revenue: $164.9 million, including $51.7 million from collaboration and license revenue, which featured a $40 million milestone from CSL Vifor.

Net Income: $25.7 million ($0.29 per share), a significant improvement from a net loss of $54.8 million in Q3 2024.

Cash Position: $254.5 million as of September 30, 2025, following the repayment of $69 million in convertible notes.

2Strategic Updates and Business Highlights

FILSPARI Growth: Continued strong adoption in IgA nephropathy, driven by positive real-world outcomes and inclusion in KDIGO guidelines as a foundational therapy.

FDA Engagement: Positive progress on the supplemental NDA for FILSPARI in FSGS, with no advisory committee required, aiming for approval in January 2026.

Manufacturing Advances: Successful production of commercial-scale batches of pegtibatinase, with plans to restart the pivotal HARMONY study in 2026.

Global Expansion: Strong international collaboration efforts, particularly in Europe and Japan, with significant milestones achieved.

3Forward Guidance and Outlook

FILSPARI Launch in FSGS: If approved, a rapid launch is planned for January 2026, leveraging existing prescriber relationships from IgA nephropathy.

Sustained Growth: Confidence in continued revenue growth driven by FILSPARI, with expectations for higher patient start forms in Q4 2025.

Investment in R&D: Anticipated increases in R&D and SG&A expenses due to preparations for the FSGS launch and ongoing clinical trials.

4Bad News, Challenges, or Points of Concern

Gross to Net Impact: Anticipated higher discounts in Q4, which may affect revenue recognition.

Competitive Pressures: While FILSPARI has shown resilience against competitive products, the evolving landscape may pose challenges as new therapies enter the market.

Seasonality Effects: Some seasonal declines in patient start forms were noted, although less impactful than previous years.

5Notable Q&A Insights

REMS Modification Impact: The recent changes to the REMS program have been positively received, aiding in the expansion of the patient population.

Off-label Use in FSGS: Limited off-label use of FILSPARI in FSGS is occurring, though the company does not promote this.

KDIGO Guidelines: The publication of the KDIGO guidelines has reinforced FILSPARI's position, with nephrologists increasingly recognizing its benefits.

Future Communication: The company will enter a quiet period leading up to the FSGS PDUFA date, limiting updates during that time. Overall, Travere Therapeutics demonstrated strong financial performance and strategic progress in Q3 2025, with a focus on expanding its market presence and preparing for potential new product launches, while remaining aware of competitive dynamics and market challenges.